June 19 (Reuters) - Vbi Vaccines Inc VBIV.O
* Vbi Vaccines reports positive outcome from phase III pre-ind discussions with the FDA for Hepatitis B vaccine, Sci-B-Vac(tm)
* VBI Vaccines - confirm initial ind for Sci-B-Va will not require any additional clinical studies to support pivotal, global phase III clinical program
* Says VBI plans to submit ind in second half of 2017, together with clinical trial applications for Europe and Canada Source text for Eikon: ID:nCCN0cHnqa Further company coverage: VBIV.O